

*Hybrid*

**AMMF 2023 EUROPEAN  
CHOLANGIOCARCINOMA  
CONFERENCE**

**10-12 May 2023**

---

**PROGRAMME**



# We aim to lead a revolution in oncology to redefine cancer care



AstraZeneca are platinum sponsors of the Congress.

©2023 AstraZeneca. All rights reserved. Z4-53940 April 2023

Chairman’s Welcome.....	3
Co-Chairs’ Welcome .....	4-5
About AMMF .....	6-7
AMMF European Website.....	9
World Cholangiocarcinoma Day .....	11
Global Cholangiocarcinoma Alliance .....	11
Presenters .....	12-19
Programme.....	20-29
Poster Presentations 2023 .....	30-31
Cholangiocarcinoma-UK.....	32
Acknowledgements .....	33

### Disclaimer

AMMF’s 2023 Hybrid European Cholangiocarcinoma Conference is an international hybrid event run by AMMF and provided to international Healthcare Professionals from around the world. Please note that any prescribing information which may be provided may vary depending on local approval in each country. For purposes of the conference, best efforts were undertaken by AMMF and conference sponsors to ensure compliance with ABPI guidelines, however, you should review your local prescribing information and consult directly with the local affiliate of the relevant company to address any questions.

*If you are not a Healthcare Professional, please be aware that, to comply with international pharmaceutical guidelines, certain areas of the meeting platform and conference programme are intended for Healthcare Professionals only and clear guidance will be provided for these areas.*

#AMMF2023

 [facebook.com/CharityAMMF](https://facebook.com/CharityAMMF)

 [charityammf](https://twitter.com/charityammf)  [charityammf](https://www.instagram.com/charityammf)

[www.ammf.org.uk](http://www.ammf.org.uk)



**BASL Endorsed**  
AMMF’s conference is a BASL endorsed event.



THE CPD STANDARDS OFFICE  
CPD PROVIDER 41095  
2023-2025  
[www.cpdstandards.com](http://www.cpdstandards.com)

**CPD Registered**  
AMMF’s conference is CPD accredited. Registered delegates attending/logging in to the conference will be awarded **18.05** hrs CPD. A CPD Certificate of Attendance will be available on request after the conference.



# Putting the spotlight on cholangiocarcinoma



## Visit

[www.cholangiocarcinoma-eu.com/patients](http://www.cholangiocarcinoma-eu.com/patients)  
for cholangiocarcinoma-related information,  
resources and plain language meeting summaries  
aimed at patients and their carers\*



Scan for patient  
resources\*



\*Available for patients and carers based in the UK, Netherlands, Belgium and France.  
UK/CCA/NP/23/0007  
Date of preparation: April 2023  
Incyte Biosciences International Sàrl  
Rue Docteur-Yersin 12  
1110 Morges, Switzerland

Funded and developed by Incyte Biosciences International Sàrl.  
© 2023, Incyte. All rights reserved.  
The Incyte logo is a registered trademark of Incyte.



Noel Corrigan  
Chair of Trustees – AMMF

Dear Friends

It is my great pleasure to welcome you to AMMF's Hybrid 2023 European Cholangiocarcinoma Conference.

Once again I am delighted to be able to welcome you both face-to-face and virtually, something which is enabling global participation. I would like to thank our co-chairs – Professor John Bridgewater and Professor Lorenza Rimassa – for agreeing to keep things on track for us.

I am grateful to all AMMF's benefactors, many of whom are in attendance, without whose support this conference would not be possible, and who enable much of the work reported on here by our international community of researchers and practitioners. I extend a particular welcome to those patients, carers, family, and friends who are able to join us.

I am privileged to welcome you to this year's event, dedicated to innovation. Over the 21 years since AMMF's inception the charity has grown in ways we could not have imagined, and so has the understanding of cholangiocarcinoma. We still have a long way to go, but I hope you will be heartened by what you will hear over the next three days from every area of the cholangiocarcinoma arena from the UK, Europe and across the globe.

The conference offers something for everyone – patients and carers, practitioners, researchers, pharma, and I would encourage you all to exploit the opportunities for interaction over the coming days, both physical and virtual. I hope that such networking will foster new ideas and collaborations that will help us to progress to earlier diagnosis, more effective treatments, and ultimately a cure for this most challenging of diseases.

I wish everyone an enjoyable and fruitful conference.

Noel Corrigan  
Chair of Trustees – AMMF  
[noel@ammf.org.uk](mailto:noel@ammf.org.uk)



Professor John Bridgewater



Professor Lorenza Rimassa

Dear Friends and Colleagues

We are delighted to welcome you all to AMMF's European Cholangiocarcinoma Conference 2023.

This event brings together an expert international faculty with speakers who will deliver an engaging hybrid event that will explore all aspects of cholangiocarcinoma (CCA).

On behalf of AMMF we will be hosting world-renowned speakers from across the globe who will speak of innovations and advances made in our understanding and treatment of CCA, and discuss the importance of accelerating the progress we are now seeing.

Our role as Co-chairs is to facilitate and encourage the sharing of information amongst all attendees, both in person and virtually, and throughout the meeting there will be several Q&A sessions aimed to ensure your questions are answered, and we look forward to your contributions.

We would also like to take the opportunity thank AstraZeneca, Incyte, Taiho Oncology, Jazz Pharmaceuticals and Servier, whose support has made this gathering and sharing of advances possible.



AMMF conference scenes...

Finally, a special thank you to Helen Morement, CEO of AMMF, for her kind invitation to co-chair this important meeting and her ongoing commitment and dedication to those impacted by CCA.

We wish you all an enjoyable three days and safe onward travels.

Professor John Bridgewater  
University College London, UK

Professor Lorenza Rimassa  
Humanitas University and IRCCS  
Humanitas Research Hospital, Milan, Italy

Working throughout the UK and Europe, collaborating throughout the world for those with cholangiocarcinoma, AMMF is actively involved with many groups, organisations and ventures, national and international, including:



a member of  
**cancer52**  
the common voice  
for less common cancers



When AMMF was founded and registered with the Charity Commission in 2002, it was the world's first charity dedicated solely to cholangiocarcinoma. It remains the UK's only dedicated cholangiocarcinoma charity, now working nationally, across Europe and also actively collaborating globally.

Over recent years an enormous and extremely worrying global increase in cholangiocarcinoma's incidence has been noted. The incidence appears to be increasing across all age groups, including younger people, and the cause of this ongoing increase is unknown. Much more research is desperately needed.

Throughout the last 21 years, AMMF has been, and remains, totally committed to tackling this devastating cancer on all fronts: providing information and support, campaigning to raise awareness, and encouraging and supporting specialised research teams, nationally and internationally in their work towards better diagnostic techniques and treatments and, ultimately a cure.

Dedicated to bringing about improvement for the cholangiocarcinoma patient, AMMF works closely with patients and their carers, clinicians, healthcare professionals, researchers, politicians and policy makers, and is actively involved with many groups, organisations and ventures, national and international.

### OUR MISSION

A world improved for the cholangiocarcinoma patient by the sharing of knowledge across the healthcare and research communities and with the family of affected people across the globe.

Registered charity no 1198095





# Stop cholangiocarcinoma striking before it's too late.

CCA\* is on the rise, and 20-25%<sup>1</sup> of patients are diagnosed by chance. Early detection can save lives.

**Think CCA**

Be aware of high-risk factors: PSC<sup>†</sup>, Gallstones, Liver Flukes, Cirrhosis and common risk factors: Smoking, Diabetes, NAFLD<sup>\*\*</sup>

For the attention of HCPs only

\*CCA – Cholangiocarcinoma, bile duct cancer  
<sup>†</sup>PSC, primary sclerosing cholangitis  
<sup>\*\*</sup>Non alcoholic fatty liver disease  
<sup>1</sup>Banales, JM et al. *Nat Rev Gastroenterol Hepatol* 2020;17:557-588

LAUNCHED!

AMMF EUROPEAN WEBSITE

Expanding the reach of AMMF across Europe!

#AMMFEUWebsite

AMMF, the UK's only cholangiocarcinoma (CCA) charity, is committed to supporting not only those in the UK, but also European patients and carers living with CCA, through greater access to the information, resources and support they deserve.

Additional to AMMF's main, and comprehensive website, a new AMMF European CCA Website was launched on World CCA Day, in February 2022. This website will help to raise awareness and provide guidance and information on CCA in 8 European languages:

- |         |        |         |            |
|---------|--------|---------|------------|
| Danish  | French | Italian | Portuguese |
| Finnish | German | Polish  | Spanish    |

The new European CCA website will support patients and their carers/loved ones seeking information on all aspects of CCA across Europe, as well as helping healthcare practitioners, including clinical nurse specialists, to navigate information available for their patients with CCA.

Visit the AMMF European CCA Website here: [ammf-eu.org](https://ammf-eu.org)

AMMF thanks the following for their generous support for the European Cholangiocarcinoma Website:



Sponsors do not control nor influence the work of AMMF, nor the projects the charity supports.

# Collaborative Dynamic

## Patient-Centered

At Taiho Oncology, our mission is to improve the lives of patients with cancer, their families, and their caregivers. Taiho provides innovative medicines in Europe and worldwide.

Visit <https://www.taihooncology.eu/> to learn more.

© Taiho Oncology Europe GmbH. All rights reserved. 03/2023 TOI-PM-US-0719 v1

**TRANSFORMING LIVES. REDEFINING POSSIBILITIES.**

**Jazz Pharmaceuticals is proud to sponsor the  
AMMF 2023 European Cholangiocarcinoma Conference**



Jazz Pharmaceuticals is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options.



[www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com)

© 2023 Jazz Pharmaceuticals plc. All rights reserved. JPC-28298-0422



# WORLD CHOLANGIOCARCINOMA DAY

AMMF strongly believes collaboration is the way towards progress and is proud to have instigated the first World Cholangiocarcinoma Day in 2016.

This international venture, founded on the ethos of working with a nationally neutral but globally inclusive voice, has continued to grow in influence as it works to raise awareness and to address the many unmet needs of cholangiocarcinoma patients throughout the world.

[www.globalccaalliance.com/en/world-cca-day](http://www.globalccaalliance.com/en/world-cca-day)

## GLOBAL CHOLANGIOCARCINOMA ALLIANCE

Leading cholangiocarcinoma specialists and patient advocates from around the world met at an international workshop led by AMMF in London in 2018. There they shared the vision to make significant and increased global awareness, and progress for cholangiocarcinoma’s diagnosis, treatment, cure, and eventual eradication – and the Global Cholangiocarcinoma Alliance began.

Launched on World CCA Day 2019, The Global Cholangiocarcinoma Alliance, led by an international steering committee of CCA specialists and patient advocates, is now working towards greater global collaborations with a comprehensive portfolio of initiatives to provide the worldwide cholangiocarcinoma community with a platform to build links and exchange knowledge to deliver the shared vision.

[www.globalccaalliance.com](http://www.globalccaalliance.com)



“This multidisciplinary group is much-needed in tackling cholangiocarcinoma. It’s not something one organisation can do; it needs gifted people from a variety of backgrounds to make a difference.”

*Professor Shabid A Khan,  
Imperial College London*



## PRESENTERS

---



**Helen Morement**

*Founder and CEO*

AMMF – The Cholangiocarcinoma Charity



**Noel Corrigan**

*Chair of Trustees*

AMMF – The Cholangiocarcinoma Charity



**Harry Corrigan**

*Treasurer, Trustee*

AMMF – The Cholangiocarcinoma Charity



**Professor John Bridgewater**

*Consultant Medical Oncologist*

University College Hospital London

*Clinical Researcher*

UCL Cancer Institute, London



**Professor Robert Goldin**

*Professor of Liver and GI Pathology*

Faculty of Medicine, Department of  
Metabolism, Digestion and Reproduction,  
Imperial College London

Ludwig Institute of Cancer Research  
University of Oxford



**Mr Hassan Z Malik**

*Consultant General and  
Hepatobiliary Surgeon*

Clinical Director for Digestive Surgery,  
Liverpool University Hospitals NHS  
Foundation Trust



**Professor Juan Valle**

*Professor of Medical Oncology*


University of Manchester and  
The Christie



**Dr Ganesh Radhakrishna**

*Consultant Clinical Oncologist*

The Christie NHS Foundation Trust,  
Manchester



**Professor Lorenza Rimassa**

*Professor of Medical Oncology*

Deputy Director, Medical Oncology Unit  
Himantitas Cancer Center, Italy



**Professor Shahid A Khan**

*Professor of Practice (Hepatology)*

Imperial College NHS Trust,  
Faculty of Medicine,  
Imperial College London



**Louise Jones**

*Clinical Nurse Specialist*

Liverpool University Hospitals NHS  
Foundation Trust



**Margaret Griffin**

*Clinical Nurse Specialist*

Liverpool University Hospitals NHS  
Foundation Trust

*See more presenters overleaf*

## PRESENTERS

---



## PRESENTERS

---



**Paolo Leonardi**  
*Founder & President*  
APiC advocacy group



**Masako Watanabe**  
*Founder*  
Daisy Ass advocacy group



**Dr Heinz-Josef Klumpen**  
*Medical Oncologist*  
Amsterdam UMC, University of  
Amsterdam Cancer Center Amsterdam,  
The Netherlands



**Dr Naureen Starling**  
*Consultant Medical Oncologist*  
The Royal Marsden, London



**Dr Ruengsin Thuennadee**  
*Chair*  
The Cholangiocarcinoma Foundation,  
Thailand



**Stacie C. Lindsey**  
*Founder & CEO*  
The Cholangiocarcinoma Foundation,  
USA




**Dr Chris Wadsworth**  
*Consultant Gastroenterologist  
and HPB Physician*  
Imperial College Healthcare NHS Trust



**Professor John Primrose**  
*Professor of Surgery*  
University of Southampton



**Dr Sophie Jose**  
*Senior Health Data Analyst*  
Health Data Insight CIC,  
Cambridge



**Judith Neptial**  
*Patient Presenter*



**Ms Rachel Guest**  
*Honorary HPB Consultant Surgeon*  
Royal Infirmary of Edinburgh  
Senior Clinical Lecturer  
The University of Edinburgh



**Catarina Simões Padilla**  
Netherlands Cancer Institute,  
The Netherlands

*See more presenters overleaf*

## PRESENTERS

---

## PRESENTERS


---



**Dr Simon Rushbrook**  
*Consultant in Gastroenterology  
& Hepatology*  
Norfolk and Norwich University  
Hospitals NHS



**Dr Julien Edeline**  
*Medical Oncologist*  
Centre Eugene Marquis  
Rennes, France



**Dr Kefei Yuan**  
Laboratory of Liver Surgery,  
West China Hospital,  
Sichuan University, China




**Dr Chiara Braconi**  
*Clinician Scientist*  
Institute of Cancer Sciences, University of Glasgow  
*Honorary Consultant Medical Oncologist*  
Beatson West of Scotland Cancer Centre



**Professor Ross Andrews**  
*Professor of Parasitology (Hon)*  
Imperial College London and  
Khon Kaen University, Thailand



**Professor Paiboon Sithithaworn**  
Department of Parasitology and  
the Liver Fluke and Cholangiocarcinoma  
Research Center  
Faculty of Medicine Khon Kaen University,  
Thailand




**Dr Shirin E Khorsandi**  
King's College Hospital, London




**Dr Tim Kendall**  
*Honorary Consultant Pathologist*  
Royal Infirmary of Edinburgh



**Dr Angela Lamarca**  
*Consultant in Medical Oncology*  
Fundación Jimenez Diaz University  
Hospital, Madrid, Spain



**Professor Maeve Lowery**  
*Consultant Medical Oncologist*  
Trinity College, Dublin



**Professor Jesper B Andersen**  
*Associate Professor*  
Andersen Group, Biotech Research and  
Innovation Centre (BRIC)  
University of Copenhagen, Denmark



**Dr Julien Calderaro**  
*Associate Professor*  
Department of Pathology  
Henri Mondor Hospital,  
Créteil, France

*See more presenters overleaf*

## PRESENTERS

---

## PRESENTERS

---



**Professor Kevin Gaston**

*Professor of Cancer Services*

School of Medicine and Biodiscovery Institute  
University of Nottingham



**Gemma Owen**

*DPhil Student in Medical Sciences*

Nuffield Division of Clinical Laboratory Sciences  
Radcliffe Department of Medicine  
University of Oxford



**Dr Valerie Crolley**

*Clinical Research Training Fellow*

Research Department of Oncology  
Cancer Institute, UCL



**Dr Daniel DiToro**

*Molecular and Genetic*

*Pathology Fellow, MGB  
Clinical Fellow, HMS  
Boston, Massachusetts*



**Dr Pedro M. Rodrigues**

*Basic and Translational Scientist*

Specialized in the study of Cholangiocarcinoma  
Liver Diseases Group  
Biodonostia Health Research Institute, Spain



**Dr Anabel Martinez Lyons**

*Research Fellow*

University of Edinburgh



**Dr Laura Randle**


*Senior Lecturer in Biomolecular Science*

Liverpool John Moores University and  
The University of Liverpool



**Professor Jen Morton**

Cancer Research UK  
Beatson Institute



**Francesca Clementi**

*Patient Presenter*



**Professor Jesus Bañales**

*Head of the Liver Diseases Group*

Biodonostia Research Institute, Spain

*Professor of Sciences*

University of Navarra, Spain

*Assistant Professor Medicine/Sciences*

Mayo Clinic, USA and University of  
Area Andina, Colombia



**Associate Professor**

**Watcharin Loilome**

*Director*

Cholangiocarcinoma Research Institute  
Khon Kaen University, Thailand



**Dr Shijie Cai**

*Senior Research Associate*

Nuffield Division of Clinical Laboratory  
Sciences, University of Oxford

## PRESENTERS

---



DAY ONE – Wednesday 10th May

TIME	MIN	TOPIC	SPEAKER
14.00 – 14.30	30	Registration, early arrivals and informal meet for tea and cake	AMMF Team <i>Pre-function Room</i>
14.30 – 14.35	05	Introduction to the Co-chairs and the afternoon sessions	Helen Morement <i>CEO – AMMF</i>
<b>THE MULTIDISCIPLINARY TEAM</b>			
14.35 – 14.40	05	Introduction to the session	Professor John Bridgewater <i>UCL Cancer Institute University College Hospital London</i> Professor Lorenza Rimassa <i>Humanitas University and IRCCS Humanitas Research Hospital, Milan</i>
14.40 – 15.20	40	MDT Presentation and Discussions	Professor Shahid A Khan <i>Hepatologist</i> Professor Rob Goldin <i>Pathologist</i> Mr Hassan Z Malik <i>Surgeon</i> Professor Juan Valle <i>Oncologist</i> Dr Ganesh Radhakrishna <i>Consultant Clinical Oncologist</i> Louise Jones/Margaret Griffin <i>HPB CNS</i>

**MDT Presentation and Discussions**

Whilst this session is open to all – patients, carers, healthcare professionals, clinical nurse specialists – its primary objective is to help patients and carers better understand the work, purpose, and importance of an experienced multi disciplinary team (MDT) in confirming the diagnosis and treatment pathway for those with cholangiocarcinoma. All are welcome to submit questions to the panel following the presentation.

Please note: Poster + Exhibitor Halls are intended for HCPs only.

TIME	MIN	TOPIC	SPEAKER
15.20 – 15.35	15	<i>Question Time</i>	<i>MDT Panel Moderated by Co-chairs</i>
<b>ADVOCACY VIEWPOINT</b>			
15.35 – 15.40	05	Introduction to the work of Advocacy Groups	Professor John Bridgewater Professor Lorenza Rimassa
15.40 – 16.30	10	APiC, Italian Association of Cholangiocarcinoma patients	Paolo Leonardi <i>Founder and President</i>
	10	The Japan Cholangiocarcinoma Association (The Daisy Association)	Masako Watanabe <i>Founder</i>
	10	The Cholangiocarcinoma Foundation, Thailand	Dr Ruengsin Thuennadee <i>Chair</i>
	10	Cholangiocarcinoma Foundation, USA	Stacie C. Lindsey <i>Founder &amp; CEO</i>
	10	AMMF – The Cholangiocarcinoma Charity, UK	Helen Morement <i>Founder &amp; CEO</i>
16.30 – 16.45	15	<i>Question Time</i>	<i>Advocacy panel Moderated by Co-chairs</i>
16.45 – 16.50	05	End of Day One	Co-chairs
16.50 – 18.30	100	<i>Break and Networking</i>	
17.00 – 18.00	60	<i>Meet the AMMF team and CNS drop-in session</i>	<i>Patient / Carer Lounge</i>
18.30 onwards		<i>Meet and Mingle Buffet</i>	
20.00 – 21.00	60	AMMF Clinical/Medical Advisors Board Meeting	Room 7 <i>Invitation Only</i>

Times shown are GMT. For CET +1 hour.

Programme continued overleaf

DAY TWO – Thursday, 11th May – Morning Session

TIME	MIN	TOPIC	SPEAKER
08.00 – 08.30	30	<i>Registration and Coffee</i>	AMMF Team <i>Pre-function Room</i>
08.30 – 08.40	10	Co-Chairs Welcome	Professor John Bridgewater <i>UCL Cancer Institute University College Hospital London</i>  Professor Lorenza Rimassa <i>Humanitas University and IRCCS Humanitas Research Hospital, Milan</i>
08.40 – 09.00	20	Overview of AMMF’s Work/ External Projects	Helen Morement <i>CEO – AMMF</i>
09.00 – 09.20	20	CCA overview	Professor Shahid A Khan <i>Imperial College London</i>
09.20 – 09.40	20	AMMF CCA Data Project overview	Dr Sophie Jose <i>Health Data Insight CIC</i>
09.40 – 09.50	10	<i>Question Time</i>	<i>Panel</i>
09.50 – 10.05	15	Patient Perspective	Judith Neptial
10.05 – 10.20	15	<i>Coffee and Networking</i>	
<b>INNOVATION IN PERSONALISED MEDICINE</b>			
10.20 – 10.25	05	Introduction to the session	Professor John Bridgewater Professor Lorenza Rimassa
10.25 – 10.45	20	Molecular profiling in the UK and Europe (what is it, mutations in CCA, etc.)	Dr Heinz-Josef Klumpen <i>Amsterdam UMC, University of Amsterdam Cancer Center Amsterdam, The Netherlands</i>

Please note: Poster + Exhibitor Halls are intended for HCPs only.

TIME	MIN	TOPIC	SPEAKER
10.45 – 11.05	20	Personalised medicine – what is it and where are we with CCA. Is this the future?	Professor Juan Valle <i>University of Manchester and The Christie</i>
11.05 – 11.20	15	<i>Question Time</i>	<i>Panel</i>
<b>INNOVATION IN THE TREATMENT LANDSCAPE</b>			
11.20 – 11.25	05	Introduction to the session	Professor John Bridgewater Professor Lorenza Rimassa
11.25 – 11.45	20	Liquid Biopsy and the ACCESS Program	Dr Naureen Starling <i>The Royal Marsden</i>
11.45 – 12.05	20	ERCP Services and CCA	Dr Chris Wadsworth <i>Imperial College Healthcare NHS Trust</i>
12.05 – 12.25	20	Centres of Expertise – what are they, why are they so needed in CCA	Mr Hassan Z Malik <i>Liverpool University Hospitals NHS Foundation Trust</i>
12.25 – 12.40	15	<i>Question Time</i>	<i>Panel</i>
12.40 – 12.45	05	AMMF Award Presentation	Noel Corrigan <i>Chair, AMMF</i> Harry Corrigan <i>Treasurer, AMMF</i>
12.45 – 13.40	55	<i>Lunch and Networking</i>	
12.50 – 13.20	15 15	<i>Video screenings</i> Nutrition for CCA patients Andrea’s AMMF Army – Thailand	The AMMF Team Andrea Sheardown  <i>Patient/Carer Lounge</i>
12.55 – 13.40	45	Poster board discussions	Room 12

Times shown are GMT. For CET +1 hour.

Programme continued overleaf

DAY TWO – Thursday, 11th May – Afternoon Session

TIME	MIN	TOPIC	SPEAKER
<b>INNOVATION IN THE TREATMENT LANDSCAPE (continued)</b>			
13.40 – 13.45	05	Introduction to the afternoon session	Professor John Bridgewater Professor Lorenza Rimassa
13.45 – 14.05	20	Surgery for bile duct cancer: Can we improve outcomes?	Professor John Primrose <i>University of Southampton</i>
14.05 – 14.25	20	Updates on the Surgical Management of Cholangiocarcinoma	Ms Rachel Guest <i>Royal Infirmary of Edinburgh</i>
14.25 – 14.40	15	<i>Question Time</i>	<i>Panel</i>
14.40 – 14.55	15	<i>Tea and Networking</i>	
<b>PARALLEL SESSION – PATIENT AND CARER PRESENTATION</b> <i>Patient/Carer Lecture Room</i>			
14.55 – 15.25	30	Health-Related Quality of Life Measurement Strategy for Solid Rare Cancers	Catarina Simões Padilla <i>Netherlands Cancer Institute, The Netherlands</i>
<b>INNOVATION IN THE TREATMENT LANDSCAPE (continued)</b>			
14.55 – 15.25	15	<i>AstraZeneca* sponsored session: HCPs only</i> From cancer of unknown primary to cholangiocarcinoma – A patient case study	Professor Juan Valle <i>University of Manchester and The Christie</i>
	15	Raising the profile of CCA in Europe	Dr Tim Kendall <i>University of Edinburgh</i>
15.25 – 15.45	20	PSC + CCA  The Aspirin Trial	Dr Simon Rushbrook <i>University of East Anglia</i> Professor Shahid A Khan <i>Imperial College London</i>

\* This presentation is a Platinum sponsor benefit.

Please note: Poster + Exhibitor Halls are intended for HCPs only.

TIME	MIN	TOPIC	SPEAKER
15.45 – 16.05	20	SIRT – A treatment for CCA?	Professor Julien Edeline <i>Centre Eugène Marquis, Rennes, France</i>
16.05 – 16.20	15	<i>Question Time</i>	<i>Panel</i>
<b>INTERNATIONAL ASPECTS OF CCA</b>			
16.20 – 16.25	05	Introduction to the session	Professor John Bridgewater Professor Lorenza Rimassa
16.25 – 16.45	20	The Professor Narong Khuntikeo Memorial Lecture	Professor Ross Andrews <i>Khon Kaen University, Thailand and Imperial College London</i>
16.45 – 17.05	20	The OV diagnosis test system	Professor Paiboon Sithithaworn <i>Khon Kaen University, Thailand</i>
17.05 – 17.25	20	Europe – Viewpoint from Spain	Dr Angela Lamarca <i>Fundacion Jimenez Diaz University Hospital, Madrid</i>
17.25 – 17.45	20	The CCA Landscape in Ireland	Professor Maeve Lowery <i>Trinity College, Dublin</i>
17.45 – 18.05	20	Circular RNAs in Cholangiocarcinoma	Dr Kefei Yuan <i>Laboratory of Liver Surgery, West China Hospital, Sichuan University, China</i>
18.05 – 18.20	15	<i>Question Time</i>	<i>International Panel</i>
18.20 – 18.25	05	End of Day Two	Professor John Bridgewater Professor Lorenza Rimassa
18.25 – 19.55	90	<i>Networking</i>	
18.25 – 19.25	60	Global CCA Alliance	Room 10 – <i>Invitation Only</i>
18.40 – 19.25	45	Poster boards	Room 12
19.55 – 21.55	120	<i>Buffet Dinner</i>	

Times shown are GMT. For CET +1 hour.

Programme continued overleaf



## DAY THREE – Friday, 12th May – Morning Session

TIME	MIN	TOPIC	SPEAKER
08.00 – 08.50	50	Cholangiocarcinoma UK Committee Meeting	Room 10 <i>Invitation only</i>
08.15 – 09.00	45	<i>Registration and Coffee</i>	AMMF Team <i>Pre-function Room</i>
09.00 – 09.10	10	Welcome to Day 3	Professor John Bridgewater <i>UCL Cancer Institute University College Hospital London</i>
			Professor Lorenza Rimassa <i>Humanitas University and IRCCS Humanitas Research Hospital, Milan</i>
<b>CCA SPECIALIST GROUP UPDATES</b>			
09.10 – 09.30	20	ENS-CCA – Overview and update	Dr Chiara Braconi <i>Chair – ENS-CCA</i>
09.30 – 09.50	20	CCA-UK – Overview and update	Professor Shahid A Khan <i>Chair – CCA-UK</i>
09.50 – 10.00	10	<i>Question time</i>	<i>Panel</i>
<b>BIG DATA</b>			
10.00 – 10.05	05	Introduction to the session	Dr Shirin Elizabeth Khorsandi <i>Kings College, London</i> Dr Tim Kendall <i>University of Edinburgh</i>
10.05 – 10.25	20	Molecular data: Implications of genomics in cholangiocarcinoma	Professor Jesper B Andersen <i>University of Copenhagen, Denmark</i>

Please note: Poster + Exhibitor Halls are intended for HCPs only.

TIME	MIN	TOPIC	SPEAKER
10.25 – 10.45	20	How can AI inform physician's decisions?	Professor Julien Calderaro <i>Henri Mondor University Hospital, France</i>
10.45 – 11.05	20	Exploring Protein Kinase CK2 inhibition and identifying new targets	Professor Kevin Gaston <i>University of Nottingham</i>
11.05 – 11.20	15	<i>Question time</i>	<i>Panel</i>
11.20 – 11.35	15	<i>Coffee and Networking</i>	
<b>NOVEL FINDINGS IN CCA RESEARCH</b>			
11.35 – 11.40	05	Introduction to the session	Professor John Bridgewater Professor Lorenza Rimassa
11.40 – 11.55	15	The role of normal cholangiocytes in regulating cholangiocarcinoma cells during co-culture	Gemma Owen <i>University of Oxford</i>
11.55 – 12.10	15	KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor	Dr Pedro M. Rodrigues <i>Biodonostia Health Research Institute, Spain</i>
12.10 – 12.25	15	A Notch signalling niche drives the initiation and early growth of cholangiocarcinoma	Dr Anabel Martinez Lyons <i>University of Edinburgh</i>
12.25 – 12.50	25	<i>Question Time</i>	<i>Panel</i>
12.50 – 13.05	15	Patient Perspective	Francesca Clementi
13.05 – 14.05	60	<i>Lunch and Networking</i>	

Times shown are GMT. For CET +1 hour.

Programme continued overleaf

DAY THREE – Friday, 12th May – Afternoon Session

TIME	MIN	TOPIC	SPEAKER
13.30 – 14.00	15	<i>Video screenings</i> Nutrition for CCA patients	The AMMF Team
	15	Andrea's AMMF Army – Thailand	Andrea Sheardown <i>Patient/Carer Lounge</i>
<b>TRANSLATION INTO CLINICAL PRACTICE</b>			
14.05 – 14.10	05	Introduction to the afternoon session	Professor John Bridgewater Professor Lorenza Rimassa
14.10 – 14.30	20	The ENSCCA clinical database: current status, studies and new results	Professor Jesus Bañales <i>Biodonostia Institute, Spain</i>
14.30 – 14.50	20	Biomarkers from the BILCAP series: Focus on HER2	Dr Valerie Crolley <i>University College Hospital London</i>
14.50 – 15.10	20	Acquired resistance to FGFR inhibitors	Dr Daniel DiToro <i>Massachusetts, USA: Brigham and Women's Hospital, Boston Massachusetts General Hospital, Boston Ragon Institute of MGH, MIT and Harvard, Cambridge Harvard Medical School, Boston</i>
15.10 – 15.25	15	<i>Question Time</i>	<i>Panel</i>
15.25 – 15.40	15	<i>Tea and Networking</i>	

Please note: Poster + Exhibitor Halls are intended for HCPs only.  
Times shown are GMT. For CET +1 hour.

TIME	MIN	TOPIC	SPEAKER
<b>WORKSHOP ON PRECLINICAL MODELS</b>			
15.40 – 15.45	05	Introduction to the session	Dr Chiara Braconi <i>Beatson West of Scotland Cancer Centre</i>
15.45 – 16.05	20	Characterisation of a precision cut tumour slice model to explore cholangiocarcinoma	Dr Laura Randle <i>Liverpool John Moores University and The University of Liverpool</i>
16.05 – 16.25	20	Novel genetically engineered mouse models of cholangiocarcinoma	Professor Jen Morton <i>Cancer Research UK Beatson Institute</i>
16.25 – 16.40	15	<i>Question time</i>	<i>Panel</i>
<b>HIGHLIGHTS OF THE CONFERENCE</b>			
16.40 – 16.50	10	Conference highlights	Professor John Bridgewater Professor Lorenza Rimassa
16.50		<i>Conference Close</i>	

Join us again next year

**AMMF 2023 European Cholangiocarcinoma Conference**  
10 – 12 May 2023 (tbc)

Venue: Radisson Blu Hotel, Stansted Airport, UK



The following posters can be viewed in the Conference Poster Hall, where each of the authors can be heard presenting their work.

**1 Ainhoa Lapitz, Biodonostia Health Research Institute, San Sebastian**

Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma

**2 Paula Olaizola, Biodonostia Health Research Institute, San Sebastian**

Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma

**3 Aloña Agirre Lizaso, Biodonostia Health Research Institute, San Sebastian**

Scavenger receptor MARCO is associated with an immunosuppressive microenvironment and tumor progression in intrahepatic cholangiocarcinoma

**4 Irene Olaizola, Biodonostia Health Research Institute, San Sebastian**

Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms

**5 Sarah Al-Shakhshir, Sandwell and West Birmingham Hospitals NHS Trust**

Survival outcomes in patients undergoing liver transplantation for primary sclerosing cholangitis (PSC) and incidental cholangiocarcinoma

**6 Juan W Valle, University of Manchester and The Christie NHS Foundation Trust**

Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the Phase 3 TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)

**7 Juan W Valle, University of Manchester and The Christie NHS Foundation Trust**

Impact of mutation status on efficacy outcomes in TOPAZ-1: A Phase 3 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)

**8 Alan MacDonald, The Royal Marsden Hospital, Sutton**

Prolonged clinical benefit with futibatinib in a patient with *FGFR2* fusion-positive intrahepatic cholangiocarcinoma previously treated with an ATP-competitive FGFR inhibitor: case report

**9 Pietro Carotenuto TIGEM, Pozzuoli, and University of Naples**

MiR181c/d regulates drug-sensitivity by targeting SIRT1 in cholangiocarcinoma

**10 Teresa Perra, University of Sassari**

Current evidence about preoperative evaluation for major hepatic resections in patients with cholangiocarcinoma

**11 John Bridgewater, UCL Cancer Institute, London**

Brightline-2: MDM2-p53 antagonist BI 907828 in patients with advanced, *MDM2*-amplified, *TP53* wild-type BTC, PDAC or other selected solid tumours

**12 Valerie Crolley, UCL Cancer Institute, London**

The impact of alterations in cancer driver genes and other potentially targetable mutations on progression and overall survival in patients with intrahepatic cholangiocarcinoma (iCCA) treated on the randomised phase III multicentre BILCAP clinical trial

Please note: the Poster Hall is intended for HCPs only.





# CHOLANGIOCARCINOMA-UK

Instigated in 2018, Cholangiocarcinoma-UK is a group affiliated to the British Association for the Study of the Liver (BASL).



This is a multi-disciplinary group of clinicians, scientists and patient advocates whose purpose is to facilitate collaborative research, enhance service development and raise the awareness of cholangiocarcinoma.

The specific aims of Cholangiocarcinoma-UK are to:

- Facilitate basic science and clinical research as well as sample collection, including for biomarker development
- Improve the pathway to collaborative clinical trials and opportunities for research funding
- Update national guidelines and advise on policy and best practice
- Optimise and standardise clinical management across the country
- Monitor epidemiological trends accurately

Current members of the Cholangiocarcinoma-UK Steering Committee are:

Chair	Professor Shahid Khan*	Imperial College, London
Secretary	Professor Derek Manas*	Freeman Hospital, Newcastle upon Tyne
Patient advocate	Helen Morement*	AMMF – The Cholangiocarcinoma Charity
Basic science representatives	Professor David Bates	University of Nottingham
	Dr Luke Boulter	MRC Human Genetics Unit, Edinburgh
	Dr Chiara Braconi	University of Glasgow
	Dr Sheela Jayaraman	University of Birmingham
Endoscopy representative	Professor Steve Pereira	University College/Royal Free Hospital, London
Hepatology representative	Dr Simon Rushbrook	Norfolk & Norwich University Hospitals
Clinical oncology representative	Professor Maria Hawkins	University College, London
Medical oncology representatives	Professor John Bridgewater*	University College, London
	Professor Juan Valle	Christie NHS Foundation Trust/ University of Manchester
Pathology representative	Dr Tim Kendall	University of Edinburgh/ Royal Infirmary Edinburgh
Surgery representatives	Professor Brian Davidson	Royal Free Hospital, London
	Professor Nigel Heaton	King's College Hospital, London
	Mr Hassan Malik	Aintree University Hospital
Trainee representatives	Dr Pilar Acedo	University College, London
	Dr Leonard Marc Quinn	University of Liverpool
	Dr Isioma Egbuniwe	University of Nottingham

\* Also members of the CCA-UK Executive Committee

[www.basl.org.uk/index.cfm/content/page/cid/28](http://www.basl.org.uk/index.cfm/content/page/cid/28)

AMMF thanks the following for their generous support for the European Cholangiocarcinoma Conference 2023:

## PLATINUM SPONSORS



## GOLD SPONSOR



## SILVER SPONSOR



## BRONZE SPONSOR



Sponsors do not control nor influence the work of AMMF, nor the projects the charity supports.



**AMMF – The UK’s only  
cholangiocarcinoma charity**

Working throughout the UK  
and Europe, collaborating  
throughout the world for those  
with cholangiocarcinoma

**[www.ammf.org.uk](http://www.ammf.org.uk)**  
**[www.ammf-eu.org](http://www.ammf-eu.org)**

Enterprise House  
Bassingbourn Road, Stansted  
Essex CM24 1QW. UK

Tel: +44 (0)1279 661479  
Email: [info@ammf.org.uk](mailto:info@ammf.org.uk)



Follow us on Facebook, Twitter, Instagram and Linked In – charityAMMF